

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/597,646
Filing Date	August 2, 2006
First Named Inventor	Phenil Patel
Art Unit	1617
Examiner Name	Not Assigned
Attorney Docket Number	PC32419A

Sheet 1 of 3

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A18	US- 5,384,318	01-24-1995	Pfizer Inc	
	A2	US- 5,246,965	09-21-1993	Ciba-Geigy	
	A3	US- 6,342,510	01-29-2002	G. D. Searle & Co.	
	A4	US- 5,932,598	08-03-1999	G. D. Searle & Co.	
	A5	US- 6,436,987	08-20-2002	Pfizer Inc	
	A6	US- 5,550,152	08-27-1996	Pfizer Inc	
	A7	US- 6,417,382	07-09-2002	Boehringer Ingelheim Pharma	
	A8	US- 6,197,753	03-06-2001	Boehringer Ingelheim KG	
	A9	US- 6,122,286	09-19-2000	Siemens Aktiengesellschaft	
	A10	US- 5,552,435	09-03-1996	Pfizer Inc	
	A11	US- 6,051,601	04-18-2000	Pfizer Inc	
	A12	US- 5,466,823	11-14-1995	G. D. Searle & Co.	
	A13	US- 5,633,272	05-27-1997	G. D. Searle & Co.	
	A14	US- 5,932,598	08-03-1999	G. D. Searle & Co.	
	A15	US- 5,521,207	05-28-1996	G. D. Searle & Co.	
	A16	US- 5,474,995	12-12-1995	Merck Frosst Canada Inc	
	A17	US- 5,310,951	05-10-1994	G. D. Searle & Co.	
	A18	US- 2002/0107276	08-08-2002	Pharmacia Corporation	para.0015, 0023, clms1, 10
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	B1	WO04/047824	06-10-2004	Boehringer Ingelheim Phar		
	B2	WO97/21670	06-19-1997	Boehringer Ingelheim KG		
	B3	WO98/03484	01-29-1998	Merck Frosst Canada Inc		
	B4	WO04/013148	02-12-2004	Boehringer Ingelheim Phar	p.3,line18;p.6,line4	
	B5	EP1270000	01-02-2003	Pfizer Products Inc	p.6,line15,ex.1	
	B6	EP1167363	01-02-2002	Pfizer Products Inc	par. 0001, examples	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND**

TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/597,646
Filing Date	August 2, 2006
First Named Inventor	Phenil Patel
Art Unit	1617
Examiner Name	Not Assigned
Attorney Docket Number	PC32419A

Sheet 2 of 3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	C1	NEEDLEMEN, P., et al., The Discovery and Function of COX-2, The Journal of Rheumatology, 1997, 6-8, Vol. 24, Suppl. 49	
	C2	JENNEWEIN, H.M., et al., Prog. Respir. Res. Basel. Karger, 2001, Vol. 31, 121-125	
	C3	ALTEN, R., et al., Inhibition of Leukotriene..., Ann Rheum Dis. 2004, 170-176, 63	
	C4	HOCHBERG, M.C., Early Aggressive DMARD Therapy: The Key to Slowing Disease Progression in Rheumatoid Arthritis, Scand J Rheumatol Suppl. 1999, 3-7, 112	
	C5	TYLE, P., Iontophoretic Devices for Drug Delivery, Pharmaceutical Research, 1986, 318-326, Vol. 3, No. 6, 1986	
	C6	O'REILLY, D., et al., Baculovirus Expression Vectors: A Laboratory Manual, 1992	
	C7	GIERSE, J., et al., Expression and Selective Inhibition of the Constitutive and Inducible Forms of Human Cyclo-Oxygenase, J. Biochem., 1995, 479-484, 305	
	C8	SUMMERS, M., et al., A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures, Texas Agric. Exp. Station Bull. 1555, 1987	
	C9	CHENG, J., et al., Tissue Distribution and Functional Correlation..., 1985, 80-87, Vol. 232, No. 1	
	C10	STUART, J., et al., Collagen Autoimmune Arthritis, Annual Rev. Immunol. 1984, 199-218, 2	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/597,646
				Filing Date	August 2, 2006
				First Named Inventor	Phenil Patel
				Art Unit	1617
				Examiner Name	Not Assigned
Sheet	3	of	3	Attorney Docket Number	PC32419A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
	C11	WOOLEY, P., et al., Genetic Control of Type II Collagen-Induced Arthritis in Mice: Factors Influencing Disease Suscept..., Transplantation Proceedings, 1983, 180-185, 15(1)		
	C12	JONSSON, R., A Demineralization Procedure for Immunohistopathological Use, J. Immunol. Methods, 1986, 109-114, 88		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**

**Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

*If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.*